Analysts Offer Predictions for Immatics FY2025 Earnings

Key Points

• Chardan Capital predicts that Immatics N.V. will report a FY2025 EPS of ($1.47), significantly lower than the current consensus estimate of ($0.72) per share.
• Immatics recently reported a quarterly EPS of (0.66), missing expectations by ($0.28) and generating revenue of $6.48 million, well below the forecast of $13.05 million.
• Analyst ratings for Immatics include a mix of one Strong Buy, four Buy, one Hold, and one Sell, with a consensus price target of $13.67.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Stock analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Immatics in a note issued to investors on Monday, October 13th. Chardan Capital analyst Y. Livshits expects that the company will earn ($1.47) per share for the year. The consensus estimate for Immatics' current full-year earnings is ($0.72) per share.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.The company had revenue of $6.48 million for the quarter, compared to analyst estimates of $13.05 million.

Other equities analysts have also issued research reports about the stock. Guggenheim started coverage on shares of Immatics in a report on Thursday, September 18th. They issued a "buy" rating and a $16.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Immatics in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of Immatics from a "strong sell" rating to a "hold" rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $13.67.

Immatics Stock Performance

NASDAQ IMTX opened at $10.83 on Thursday. The firm's fifty day moving average price is $6.96 and its two-hundred day moving average price is $5.85. The stock has a market cap of $1.32 billion, a PE ratio of -16.66 and a beta of 1.22. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $10.95.

Institutional Investors Weigh In On Immatics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock worth $25,000 after buying an additional 2,231 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in Immatics during the second quarter valued at approximately $59,000. Engineers Gate Manager LP purchased a new position in Immatics during the second quarter valued at approximately $124,000. Fox Run Management L.L.C. purchased a new position in Immatics during the second quarter valued at approximately $136,000. Finally, Exchange Traded Concepts LLC lifted its holdings in Immatics by 94.5% during the first quarter. Exchange Traded Concepts LLC now owns 25,580 shares of the company's stock valued at $115,000 after purchasing an additional 12,425 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.